Phase 3
Completed N=249
Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer
Source: ClinicalTrials.gov NCT00293540 ↗Enrolled (actual)
249
Serious AEs
0.4%
Results posted
Jun 2016
Primary outcomePrimary: Overall Survival — 2.14; 2.00 years
◆ Published Evidence
Emerging
11citations · ~1 / year
Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer.
Summary
This study will determine if hormone receptor positive premenopausal metastatic breast cancer patients who undergo removal of the ovaries in mid-luteal versus mid-follicular phase have a longer survival.
Linked Publications
-
Luteal versus follicular phase surgical oophorectomy plus tamoxifen in premenopausal women with metastatic hormone receptor-positive breast cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Overall Survival |
2.14; 2.00 | — |
Eligibility Criteria
Inclusion Criteria
- Estrogen receptor or progesterone receptor positive breast cancer
- Premenopausal with regular menstrual cycles
Exclusion Criteria
- Current oral contraceptives
Data sourced from ClinicalTrials.gov (NCT00293540) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.